Market Size of Global Osteoporosis Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Osteoporosis Drugs Market Analysis
The osteoporosis drugs market is expected to record a CAGR of 3.4% during the forecast period (2022-2027).
Many therapies are being followed worldwide to find reliable COVID-19 treatments. Numerous studies have suggested that in addition to drugs used to treat infections, other drugs such as the drug osteoporosis may be helpful in the treatment of COVID-19, which may boost the market. For example, according to a study published in November 2020, "General treatment of osteoporosis may help reduce the incidence of COVID-19", treatments such as denosumab, zoledronate, and calcium, are used to treat osteoporosis and COVID-19. The study was conducted by the Pompeu Fabra University, Hospital del Mar Medical Research Institute (IMIM), and Pere Virgili Health Park. According to research, treatment with osteoporosis can reduce COVID-19 infection by 30-40%.
A major factor in the market's growth is an increase in the incidence of osteoporosis. According to the study titled "Spread and experience of diagnosing osteoporosis in postmenopausal women over the age of 50: Focus on social issues", published in March 2021, the prevalence of osteoporosis was 34.8%, with a diagnosis rate of 22.1% in South Korea, the highest. The increase in the number of young people worldwide prone to bone growth is another important factor in the market's growth. For example, according to the International Osteoporosis Foundation, in 2020, 1 in 5 men and 1 in 3 women over the age of 50 may experience osteoporosis fractures in their remaining life.
In addition, the growing investment in R&D by biotechnology and pharmaceutical companies is enhancing the market's growth. For example, in October 2020, the Italian pharmaceutical authority approved the testing of human clinics with raloxifene. It is a standard orthopedic drug that may help reduce the symptoms of COVID-19. Therefore, positive results from clinical trials can lead to new treatment options, thus boosting the market's growth. However, strict government regulations are hindering the growth of the market studied.
